Dinakar Singh is the CEO of Axon Capital, a global investment firm. Mr. Singh was previously a senior Partner at Goldman Sachs, where he was global co-head of the Principal Strategies Department, which was the firm's highly profitable global equities proprietary trading and investment business.  

Mr. Singh serves on the boards of Columbia University Medical Center, The Jackson Laboratory, and New York Public Library, where he chairs the Investment Committee for the NYPL endowment and serves on the Executive Committee. He also previously served as a member of the Yale University Investment Committee and as a Trustee of Rockefeller University and Cold Spring Harbor Laboratory and served on the investment committees of both. 

Mr. Singh established the SMA Foundation in 2003 to drive development of a treatment for Spinal Muscular Atrophy, which was previously the leading genetic cause of death in young children. Through approximately $150 million of strategic investments, the Foundation successfully facilitated or drove three transformative FDA-approved treatments and helped establish SMA as a model for the potential to transform deadly rare diseases.